Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

The Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients

13. april 2021 oppdatert av: Michelle Janelsins, PhD, MPH, University of Rochester

A Phase II Study of the Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients Undergoing Chemotherapy

This research seeks to determine if a combination of low-dose ibuprofen along with a structured home-based walking and progressive resistance exercise program, EXCAP, will be effective in reducing cognitive difficulties among cancer patients receiving chemotherapy.

Studieoversikt

Detaljert beskrivelse

To conduct a feasibility pilot to assess preliminary efficacy of a 6 week course of ibuprofen (200 mg BID with does 8 hours apart) and a structured home based walking/progressive resistance program, EXCAP, alone or together, on cognitive function and levels of inflammatory molecules among cancer patients receiving chemotherapy (beginning at cycle 2). If these interventions prove to be useful and have potential benefit, they could have a substantial impact on treating cognitive difficulties experienced by cancer patients as well as improve quality of life. Moreover, if there is an effect of these interventions on cognitive functioning and inflammation, we will gain more knowledge of a possible mechanism of chemotherapy-related cognitive difficulties.

Studietype

Intervensjonell

Registrering (Faktiske)

110

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • New York
      • Rochester, New York, Forente stater, 14642
        • University of Rochester

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Must report cognitive difficulties of 3 or higher on a 0-10 scale
  • Must provide informed consent
  • Be able to read English
  • Have a primary diagnosis of cancer
  • Be able to swallow medication
  • Women of child-bearing potential must not be pregnant or become pregnant during the 6 week study
  • Agree not to take NSAIDs during the 6 week intervention period
  • Be scheduled to receive at least 2 additional cycles of oral or IV chemotherapy over the 42-day study period.
  • Must have the approval of their treating physician to begin the exercise program and receive the ibuprofen
  • Must be over 18 years of age

Exclusion Criteria:

  • Currently taking a consistent dosage of a NSAID at least 3 days a week for the last 3 months that is over 400mg daily
  • Have an allergy to ibuprofen
  • Be identified as in active or maintenance stage of exercise behavior as assessed by the single-item exercise stages of change short form
  • have physical limitations that contraindicate participation in sub-maximal physiological fitness testing or a low to moderate home-based walking and progressive resistance program
  • have a history of peptic ulcer disease within the last 12 months
  • Diagnosed with a neurodegenerative disease
  • Had a myocardial infraction within the past 6 months
  • Patients with a neutropenic episode during the first cycle of chemotherapy or at high risk for a neutropenic episode during future chemotherapy cycles at the treating physicians discretion
  • Have confirmed metastatic disease to the central nervous system
  • Have been hospitalized for a major psychiatric illness within the last 5 years

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Faktoriell oppgave
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Placebo and Home-Based Exercise
200mg placebo (taken twice a day at least 8 hours apart) for a period of 6 weeks and a progressive walking and resistance band exercise program called Exercise for Cancer Patient (EXCAP) for a period of 6 weeks.
A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period
Andre navn:
  • Trening for kreftpasienter
200mg BID and 8 hours apart
Andre navn:
  • Sukkerpille
Aktiv komparator: Ibuprofen 200mg BID, Home-Based Exercise
200mg ibuprofen (taken twice a day at least 8 hours apart) and a progressive walking and resistance band exercise program called Exercise for Cancer Patient (EXCAP) for a period of 6 weeks.
A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period
Andre navn:
  • Trening for kreftpasienter
200 mg BID and 8 hours apart
Andre navn:
  • ikke-steroide antiinflammatoriske legemidler
Placebo komparator: Placebo
200mg placebo (taken twice a day at least 8 hours apart) for a period of 6 weeks.
200mg BID and 8 hours apart
Andre navn:
  • Sukkerpille
Aktiv komparator: Ibuprofen 200 mg BID
200mg ibuprofen (taken twice a day at least 8 hours apart) for a period of 6 weeks.
200 mg BID and 8 hours apart
Andre navn:
  • ikke-steroide antiinflammatoriske legemidler

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Memory Performance as Assessed by Computerized Cognitive Assessment - Mean Values by Arm
Tidsramme: Baseline and 6 weeks
Memory performances (percent correct across delays) as assessed by the objective CANTAB delayed matching to sample task Percentage correct range (0 to 100) Higher percentage is better
Baseline and 6 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cognitive Functioning Score as Assessed by FACT-COG Questionnaire - Perceived Cognitive Impairment (PCI) - Mean Values by Arm
Tidsramme: Baseline and 6 weeks
Cognitive functioning score as assessed subjectively by a psychometrically validated instrument (FACT-COG) - Perceived Cognitive Impairment (PCI) (min=0, max=116) Higher Score is better
Baseline and 6 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. november 2010

Primær fullføring (Faktiske)

1. desember 2019

Studiet fullført (Faktiske)

1. desember 2020

Datoer for studieregistrering

Først innsendt

9. november 2010

Først innsendt som oppfylte QC-kriteriene

9. november 2010

Først lagt ut (Anslag)

10. november 2010

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. mai 2021

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. april 2021

Sist bekreftet

1. april 2021

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

Nei

IPD-planbeskrivelse

Overall study results will be presented to participants, faculty and staff at the University of Rochester Medical Center. tudy results will be presented at professional meetings and published

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere